Stock Mumak

Stock Profile

Bayer

Bayer is making operational progress with improving profitability. However, litigation and high debt continue to weigh on the outlook.

Stock Snapshot

Bayer Logo
Table HeaderTable Header
CompanyBayer AG
SectorPharmaceuticals, Chemicals & Biotechnology
ThemeSelf-medication, pharmaceuticals, and agriculture
Business ModelDevelopment and distribution of prescription drugs, health products, as well as seeds and crop protection solutions
ISINDE000BAY0017
Market Capitalizationapprox. €48.1 bn
UMBRELLA StatusActive

Mumak Score Card

Geopolitics

Industry

Fundamentals

Sentiment

Technical Analysis

Price Performance (12 Months)

Aktuelle Unternehmensmeldungen

Bayer AG
Pharmaceuticals, Chemicals & Biotechnology

Valuation Analysis: Bayer AG

ISIN: DE000BAY0017

Bayer AG is in a phase of operational stabilization. While revenue and cash flow remain under pressure, profitability is improving significantly. Management expects further progress in EBITDA by 2026. At the same time, glyphosate litigation, negative free cash flow, and high leverage remain the biggest challenges. Nevertheless, analysts still see attractive upside potential for the stock.
Compass 4 out of 5
Active icon
More research

Latest Portfolio Updates

Weekly Update

Weekly Market Overview – June 29–July 5, 2026

The healthcare sector remains in the lead, while technology and defense stocks are regaining strength. Positive impulses for the UMBRELLA
Next Update
Weekly Update

Weekly Market Overview – June 22-28, 2026

The UMBRELLA Strategy increased its focus on healthcare stocks and biotechnology. Technology showed a mixed performance, while defense stocks came
Next Update
Weekly Update

Weekly Market Overview – June 15-21, 2026

The UMBRELLA Strategy is divesting from energy stocks and further expanding its engagement in the healthcare and biotechnology sector.
Next Update
Weekly Update

Weekly Market Overview – June 8-14, 2026

AI and healthcare innovation are shaping the markets. The UMBRELLA Strategy increases its focus on quality companies and reduces cyclical
Next Update